High-Yield Urology

High-Yield Urology 2026: A Guideline-Based Review Book for the In-Service, Board, and Recertification Exams • Author @BenDropkin •

[High-Yield Urology @HighYieldUro]

🚨 @HighYieldUro 2026 Now Available!

✅ 6 new/updated guideline summaries
✅ 15 new RCTs
✅ 35 new testing pearls
✅ 15% off orders of 5+ books w/ code PROGRAM

@uro_res @uroresidency @urologylist @_backtableuro @AmerUrological @ABUrology
https://t.co/b7EVZjnzDY

[High-Yield Urology @HighYieldUro]

⏳T-minus ✌️ months until @ABUrology Part I Boards ➡️ great time to grab the fully updated 2026 edition of @HighYieldUro 🚀 https://t.co/b7EVZjnzDY

[High-Yield Urology @HighYieldUro]

⏳T-minus 3️⃣ months until @ABUrology Part I Boards ➡️ great time to start or boost your exam prep with the fully updated 2026 edition of @HighYieldUro 🚀

[High-Yield Urology @HighYieldUro]

⏳T-minus 3️⃣ months until @ABUrology Part I Boards ➡️ great time to start or boost your exam prep with the fully updated 2026 edition of @HighYieldUro 🚀

[High-Yield Urology @HighYieldUro]

🚨 @HighYieldUro 2026 Now Available!

✅ 6 new/updated guideline summaries
✅ 15 new RCTs
✅ 35 new testing pearls
✅ 15% off orders of 5+ books w/ code PROGRAM

@uro_res @uroresidency @urologylist @_backtableuro @AmerUrological @ABUrology
https://t.co/b7EVZjnzDY

[NEJM @NEJM]

In cisplatin-ineligible patients with muscle-invasive bladder cancer, enfortumab vedotin–pembrolizumab plus surgery led to better event-free survival (74.7%, vs. 39.4%) and overall survival (79.7%, vs. 63.1%) than surgery alone at 2 years. Full phase 3 KEYNOTE-905 trial results and Research Summary: https://t.co/bzVbmJXHMD

[Toni Choueiri, MD @DrChoueiri]

We keep rediscovering the same truth—hormonal biology works. Estrogen returns in prostate cancer, this time via patches, with noninferior outcomes and potentially better tolerability. Not new—just better applied. Study in @NEJM by the #Stampede group/@MRCCTU

https://t.co/Pq17ahdPgu

[High-Yield Urology @HighYieldUro]

Best of luck to all those heading to Raleigh to take down the @ABUrology Oral Boards this week!

[Tom Powles @tompowles1]

3 studies testing Perioperative immune bases therapy (EVP or Gem/Cis/Durva) in muscle invasive bladder all have shown an OS advantage vs standard of care. KN905 (EVP) is distinct in that it’s in a cisplatin ineligible population (accounting for the poor performance of the control arm). It’s also a smaller trial. The control arm of KN-B15 performed slightly better than NIAGARA (Gem/cis for both), but the trials are otherwise similar. The pCR in the EVP trails and the consistent efficacy of EVP is striking. #GU26

[High-Yield Urology @HighYieldUro]

🚨 @HighYieldUro 2026 Now Available!

✅ 6 new/updated guideline summaries
✅ 15 new RCTs
✅ 35 new testing pearls
✅ 15% off orders of 5+ books w/ code PROGRAM

@uro_res @uroresidency @urologylist @_backtableuro @AmerUrological @ABUrology
https://t.co/b7EVZjnzDY

[High-Yield Urology @HighYieldUro]

https://t.co/AVw0Ao3q2B

[Toni Choueiri, MD @DrChoueiri]

JUST IN: @US_FDA approved PARP inh Niraparib +abi/pred for BRCA2-mutated (BRCA2+) metastatic castration-sensitive prostate cancer (CSPC). Data based on AMPLITUDE trial showing rPFS benefit in the overall/BRCA population. Most benefit came from the BRCA2+ tumors: HR 0.46 (vs 0.88). Paper in @NatureMedicine led by @AttardLab @DRathkopf --Approval where therapies work Best!

Link: https://t.co/DgAuE5idLb

[Tom Powles @tompowles1]

The FDA approval of EV + Pembro in cisplatin ineligible muscle invasive bladder is based on pCR=57% & OS HR of 0.5 vs cystectomy alone. Initial systemic therapy rather than surgery is now preferable for all eligible pts. I suspect this is not the last we hear from EVP in MIBC.

[High-Yield Urology @HighYieldUro]

Best of luck to everyone gearing up to ace the @AmerUrological In-Service and @UroOnc OKAT Exams this weekend!

[High-Yield Urology @HighYieldUro]

🚨RC48-C016 @NEJM

🇨🇳 484 pts w/ untreated HER2(+) locally advanced or M1 UC ➡️ compared to chemo, combination Tx w/ disitamab (mAb to HER2) - vedotin & toripalimab (PD-1🛑) doubled med PFS (7 vs 13 mos) and med OS (17 vs 32 mos) & ⬇️ G3+ AE’s ✅ https://t.co/LhYPHNAjVU

[High-Yield Urology @HighYieldUro]

🚨 IMVigor 011 ⁦@NEJM⁩

After cystectomy for MIBC, ctDNA-guided adjuvant Atezolizumab (PD-L1 inhibitor) extended med DFS (10 vs 5 mos) and med OS (33 vs 21 mos) over placebo ✅ https://t.co/cdafbq5Zme

[High-Yield Urology @HighYieldUro]

🚨LITESPARK-015 @NEJM

🌎🌍 72 patients w/ advanced, unresectable, and/or metastatic Pheochromocytoma or Paraganglioma ➡️ all got Belzutifan (HIF-2a inhibitor) ➡️ at med f/u 30 mos, obj response rate and disease control were 26% and 85% ➡️ FDA-approved ✅ https://t.co/xMRmpfhIj9

[High-Yield Urology @HighYieldUro]

🔔 1️⃣ month to go until the @AmerUrological In-Service and @UroOnc OKAT exams ➡️ still time for a boost with @HighYieldUro 2025 📖🚀

@Uro_Res @UroResidency @urologylist @_backtableUro ⁦@ABUrology⁩ https://t.co/b7EVZjo7tw

[High-Yield Urology @HighYieldUro]

🔔 1️⃣ month to go until the @AmerUrological In-Service and @UroOnc OKAT exams ➡️ still time for a boost with @HighYieldUro 2025 📖🚀

@Uro_Res @UroResidency @urologylist @_backtableUro ⁦@ABUrology⁩ https://t.co/b7EVZjo7tw

[High-Yield Urology @HighYieldUro]

✌️ months to go!

[High-Yield Urology @HighYieldUro]

🚨T-minus 3️⃣ months to go until the @AmerUrological In-Service and @UroOnc OKAT exams ➡️ great time to get ahold of @HighYieldUro 2025 📖🚀

@Uro_Res @UroResidency @urologylist @_backtableUro @ABUrology

https://t.co/fXcTUcd9FZ

[Toni Choueiri, MD @DrChoueiri]

JUST IN: Tar200 now @US_FDA approved based on SunRise-1 phase 2 trial in BCG unresponsive NMIBC.

-Intravesical form of Gemcitabine
- CR: 82.4%/grade ≥3 AE 12.9%
- DFS 70.2% at 12m
- 51% of CRs with DOR ≥ 12 months.